Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Double-Blinded, Placebo-Controlled, 3-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending and Multiple Ascending Doses of S011806 in Healthy Participants and Multiple Doses of S011806 in Patients With Chronic Plaque Psoriasis

NCT06808815 is registered in ClinicalTrials.gov with DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company as lead sponsor.

NCT NCT06808815
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06808815 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Double-Blinded, Placebo-Controlled, 3-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending and Multiple Ascending Doses of S011806 in Healthy Participants and Multiple Doses of S011806 in Patients With Chronic Plaque Psoriasis
Lead sponsor
DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
September 22, 2021
Completion date
August 23, 2022
Enrollment
104 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

plaque psoriasis